4//SEC Filing
Bernstein Joel E. 4
Accession 0001209191-09-006754
CIK 0001302554other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 6:49 PM ET
Size
8.4 KB
Accession
0001209191-09-006754
Insider Transaction Report
Form 4
Bernstein Joel E.
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2009-01-12$0.40/sh+231,670$92,668→ 13,027,133 total - Exercise of In-Money
Common Stock Options
2009-01-12−231,670→ 0 totalExercise: $0.00From: 2005-01-12Exp: 2009-01-12→ Common Stock (231,670 underlying)
Footnotes (3)
- [F1]Effective December 15, 2008 (the "Effective Date"), the Company effectuated a 1-for-8 reverse stock split whereby each eight shares of Winston Pharmaceuticals, Inc.'s (the "Company's") common stock and preferred stock either issued and outstanding or held as treasury shares immediately prior to the Effective Date were automatically reduced and continued as one share of the Company's common stock or preferred stock, as applicable. All of the Company's outstanding securities were adjusted accordingly to reflect such reverse split.
- [F2]Reported amount excludes 12,705,386 shares of the Company's common stock beneficially owned by the reporting person's spouse. Pursuant to Rule 13d-4, the reporting person disclaims beneficial ownership of all of the shares beneficially owned by his spouse.
- [F3]Reported amount excludes options to purchase 661,913 shares of the Company's common stock, initially exercisable on 04/06/2006 and expiring on 04/06/2010, at an exercise price of $0.40.
Documents
Issuer
Winston Pharmaceuticals, Inc.
CIK 0001302554
Entity typeother
Related Parties
1- filerCIK 0001447384
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 6:49 PM ET
- Size
- 8.4 KB